Cite
HARVARD Citation
Hardy-Bessard, A. et al. (2020). First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study. Breast. pp. 256-263. [Online].